Wave Life Sciences (WVE)
Develops PRISM-based RNA medicines across editing, silencing, splicing, and RNAi.
Something off on this page? Send us feedback.
Builds investigational RNA medicines through PRISM, with programs in obesity, AATD, liver disease, DMD, and Huntington's disease. The business has one reportable segment, no approved product revenue, and collaboration economics tied to GSK.
Develops investigational RNA medicines through PRISM, a platform spanning RNAi silencing, RNA editing, splicing, and allele-selective silencing. Named programs include WVE-007 in obesity, WVE-006 in AATD, WVE-008 in PNPLA3 liver disease, WVE-N531 in DMD, and WVE-003 in Huntington's disease.
Operates as one reportable segment with public listing in the US, legal domicile in Singapore, and app headquarters centered in Cambridge, Massachusetts. Execution is focused on advancing clinical programs, matching PRISM chemistry to human-genetics targets, and managing outside development scope through the GSK collaboration.
No approved product revenue has been generated; recognized revenue is collaboration-driven. The business depends on clinical readouts, regulatory paths, partnership economics, manufacturing control, and the court-conditioned redomiciliation process.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 3, 2026 | UBS | Target | Target: $32 | Target: $13 |
| Jul 31, 2026 | Wedbush | Reiterate | Rating: —Target: $33 | Target: $12 |
| Jun 11, 2026 | New Street | Target | Target: — | Target: $13 |
| May 20, 2026 | Wells Fargo | Reiterate | Rating: —Target: $13 | Target: $14 |
| May 19, 2026 | H.C. Wainwright | Target | Target: $18 | Target: $13 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $490.6M · Total debt $43.6M · Total assets $558.3M · Shareholders' equity $453.5M
- Revenue
- $2.3M
- Operating income
- −$73.8M
- Net income
- −$69.4M
No dividends on record.
| Institutions | 93.07% | 183.40M shares | |
|---|---|---|---|
| 250 holders · as of Jun 30, 2026 | |||
| Insiders | 5.60% | 11.03M shares | |
| 12 holders · as of Aug 13, 2026 | |||
| Other | 1.33% | 2.63M shares | |
| remainder | |||
197.05M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Ra Capital Management, L.P.Institution | 13.69% | 26.98M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 9.75% | 19.20M | as of Jun 30, 2026 |
GSK plcInstitution | 9.26% | 18.25M | as of Jun 30, 2026 |
Maverick Capital LtdInstitution | 5.22% | 10.28M | as of Jun 30, 2026 |
Ken TakanashiInsiderdirector | 4.89% | 9.63M | filed Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 11, 2026 | Heidi L. Wagner | director | −7,000 | $6.01 |
| Aug 11, 2026 | Aik Na Tan | director | −432 | $6.01 |
| Aug 11, 2026 | Ken Takanashi | director | −3,864 | $6.01 |
| Aug 12, 2026 | Adrian Rawcliffe | director | −12,700 | $5.29 |
| Mar 26, 2026 | Ra Capital Management, L.P. | director, 10 percent owner: | +5,305,782 | $6.08 |
- Arrowhead Pharmaceuticals
RNAi peer in INHBE obesity, AATD liver disease, and GalNAc delivery
- Beam Therapeutics
One-time base-editing challenger in AATD genetic medicine
- Sarepta Therapeutics
Approved exon-skipping and DMD franchise competitor
- Madrigal Pharmaceuticals
PNPLA3 siRNA and MASH commercial anchor in liver disease
- uniQure
Huntington gene-therapy rival pursuing AMT-130 approval path
- Ionis Pharmaceuticals
Established ASO platform peer with Roche-partnered HD programs
- PTC Therapeutics
Oral HTT-lowering program tied to Novartis collaboration
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Wave Life Sciences | $4.35 | +2.20% | $838.4M | — | — | 12.8 | −73.9% |
| Arrowhead Pharmaceuticals | $71.89 | +4.51% | $9.69B | — | — | 14.5 | +171.0% |
| Beam Therapeutics | $26.08 | +3.23% | $2.60B | — | — | 16.7 | −94.2% |
| Sarepta Therapeutics | $20.92 | +3.87% | $2.13B | — | 36.4 | 1.1 | −34.3% |
| Madrigal Pharmaceuticals | $523.39 | +0.27% | $12.06B | — | — | 9.4 | +71.2% |
| uniQure | $45.01 | +1.58% | $3.07B | — | — | 164.6 | +11.0% |
| Ionis Pharmaceuticals | $45.65 | +1.66% | $7.46B | — | — | 8.5 | −40.7% |
| PTC Therapeutics | $66.09 | +1.27% | $5.45B | — | 53.4 | 5.4 | +101.6% |
| Median | — | 44.9 | 9.4 | +11.0% |